{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:57:24Z","timestamp":1790085444288,"version":"4.0.1"},"reference-count":58,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Circulating tumour cells (CTCs) from liquid biopsies are under current investigation in several cancers, including epithelial ovarian cancer (EOC) but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study, we report that chemosensitivity assays using liquid biopsy-derived metastatic EOC CTCs, from 10 patients, nine with stage IIIC and one with stage IV disease, in progression after systemic chemotherapy, submitted for hypoxic isolated abdominal perfusion (HAP), are both feasible and useful in predicting response to therapy. Viable metastatic EOC CTCs (&gt;5 cells\/mL for all 10 blood samples), enriched by transient culture and identified by reverse transcription polymerase chain reaction (RT-PCR) and indirect immunofluorescence (IF), were subjected to flow cytometry-based Annexin V-PE assays for chemosensitivity to several chemotherapeutic agents and by RT-PCR for tumour gene expression profiling. Using a cut-off value of &gt;80% cell death, CTC chemosensitivity tests were predictive of patient RECIST 1.1 responses to HAP therapy associated with 100% sensitivity, 50% specificity, 33% positive predictive, 100% negative predictive and 60% accuracy values. We propose that the methodology employed in this study is feasible and has the potential to predict response to therapy, setting the stage for a larger study.<\/jats:p>","DOI":"10.3390\/ijms21134813","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:47:46Z","timestamp":1594208866000},"page":"4813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-084X","authenticated-orcid":false,"given":"Stefano","family":"Guadagni","sequence":"first","affiliation":[{"name":"Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Clementi","sequence":"additional","affiliation":[{"name":"Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-5324","authenticated-orcid":false,"given":"Francesco","family":"Masedu","sequence":"additional","affiliation":[{"name":"Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammaria","family":"Fiorentini","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Sarti","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Ospedali Riuniti Marche Nord, 61121 Pesaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Colon and Rectal Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancies Unit, Colon and Rectal Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Papasotiriou","sequence":"additional","affiliation":[{"name":"Research Genetic Cancer Centre International GmbH, 6300 Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Apostolou","sequence":"additional","affiliation":[{"name":"Research Genetic Cancer Centre S.A, 53100 Florina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-6180","authenticated-orcid":false,"given":"Karl Reinhard","family":"Aigner","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Medias Klinikum GmbH &amp; Co KG, Krankenhausstr. 3a, 84489 Burghausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Zavattieri","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Medias Klinikum GmbH &amp; Co KG, Krankenhausstr. 3a, 84489 Burghausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta Rossella","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Reay","family":"Mackay","sequence":"additional","affiliation":[{"name":"Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14737140.2017.1299575","article-title":"Epidemiology and treatment patterns of epithelial ovarian cancer","volume":"17","author":"Jessmon","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.21873\/anticanres.13113","article-title":"Assessment of the applicability of Integrative Tumor Response Assays in advanced epithelial ovarian cancer","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40661-017-0055-8","article-title":"PARP inhibitors as potential therapeutic agents for various cancers: Focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers","volume":"4","author":"Sisay","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum resistant recurrent ovarian cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A Gynecologic Oncology Group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","article-title":"Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study","volume":"137","author":"Tempfer","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s13193-019-00922-9","article-title":"Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: An experience in 45 platinum-refractory ovarian cancer patients","volume":"10","author":"Aigner","year":"2019","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_15","first-page":"218","article-title":"Effects of Cancer Chemotherapeutic Agents on Dehydrogenase Activity of Human Cancer Tissue in Vitro","volume":"23","author":"Black","year":"1953","journal-title":"AJCP"},{"key":"ref_16","first-page":"1926","article-title":"Prospective clinical trial of a human tumor cloning system","volume":"43","author":"Clark","year":"1983","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1097-0142(19910101)67:1<20::AID-CNCR2820670105>3.0.CO;2-U","article-title":"A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer","volume":"67","author":"Kronmal","year":"1991","journal-title":"Cancer"},{"key":"ref_18","first-page":"5436","article-title":"Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors","volume":"45","author":"Kern","year":"1985","journal-title":"Cancer Res."},{"key":"ref_19","first-page":"86","article-title":"Three-dimensional histoculture: Origins and applications in cancer research","volume":"3","author":"Hoffman","year":"1991","journal-title":"Cancer Cells"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/gyno.1995.1145","article-title":"The subrenal capsule assay in selecting chemotherapy for ovarian cancer: A prospective randomized trial","volume":"57","author":"Heinonen","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00001813-199801000-00006","article-title":"Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer","volume":"9","author":"Kurbacher","year":"1998","journal-title":"Anticancer Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mor, G., and Alvero, A.B. (2008). The ChemoFx Assay: An Ex Vivo Chemosensitivity and Resistance Assay for Predicting Patient Response to Cancer Chemotherapy, Humana Press Inc.. Methods in molecular biology, apoptosis and cancer.","DOI":"10.1007\/978-1-59745-339-4"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2013.08.009","article-title":"A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer","volume":"131","author":"Rutherford","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2014.02.009","article-title":"A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer","volume":"211","author":"Krivak","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bjc.2014.375","article-title":"Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study","volume":"111","author":"Tian","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/GCO.0b013e32832210ff","article-title":"Chemosensitivity and chemoresistance testing in ovarian cancer","volume":"21","author":"Cree","year":"2009","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4236\/jct.2015.67059","article-title":"Detection of circulating tumor cells in patients with breast, prostate, pancreatic, colon and melanoma cancer: A blinded comparative study using healthy donors","volume":"6","author":"Papasotiriou","year":"2015","journal-title":"JCT"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1073\/pnas.1304186110","article-title":"Circulating tumor cells","volume":"110","author":"Williams","year":"2013","journal-title":"PNAS"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Bian, B., Yuan, X., Xie, G., Ma, Y., and Shen, L. (2015). Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130873"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: Potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18392","DOI":"10.1073\/pnas.1012539107","article-title":"Isolation of circulating tumor cells using a microvortex-generating herringbone-chip","volume":"107","author":"Stott","year":"2010","journal-title":"PNAS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0960-9776(09)70270-X","article-title":"The biological information obtainable from circulating tumor cells","volume":"18","author":"Cristofanilli","year":"2009","journal-title":"Breast"},{"key":"ref_35","first-page":"973","article-title":"Molecular characterization of circulating tumor cells in ovarian cancer","volume":"6","author":"Kolostova","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_37","first-page":"36","article-title":"Real-time liquid biopsies become a reality in cancer treatment","volume":"3","author":"Karachaliou","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-019-03046-3","article-title":"Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: A retrospective cohort study","volume":"146","author":"Guadagni","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Guadagni, S., Fiorentini, G., Papasotiriou, I., Apostolou, P., Masedu, F., Sarti, D., Farina, A.-R., Mackay, A.R., and Clementi, M. (2020). Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: A pilot study. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05021-5"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00432-020-03156-3","article-title":"Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy. Observational cohort study","volume":"146","author":"Guadagni","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40709-017-0068-9","article-title":"Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection","volume":"24","author":"Apostolou","year":"2017","journal-title":"J. Biol. Res. Thessalon."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000324403","article-title":"Correlation between cancer stem cells and circulating tumour cells and their value","volume":"4","author":"Toloudi","year":"2011","journal-title":"Case Rep. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1574888X0902140121163539","article-title":"Comparison of the growth curves of cancer cells and cancer stem cells","volume":"9","author":"Toloudi","year":"2014","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1593\/tlo.09193","article-title":"Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX","volume":"2","author":"Yu","year":"2009","journal-title":"Transl. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02841860801942158","article-title":"Prognostic Significance of Numeric Aberrations of Genes for Thymidylate Synthase, Thymidine Phosphorylase and Dihydrofolate Reductase in Colorectal Cancer","volume":"47","author":"Jensen","year":"2008","journal-title":"Acta Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1158\/1078-0432.CCR-1198-03","article-title":"The Role of Thymidylate Synthase as a Molecular Biomarker","volume":"10","author":"Chu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jpsychires.2010.10.008","article-title":"The role and interpretation of pilot studies in clinical research","volume":"45","author":"Leon","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4236\/jct.2019.107047","article-title":"Linearity comparison of three colorimetric cytotoxicity assays","volume":"10","author":"Papadimitriou","year":"2019","journal-title":"JCT"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.18632\/oncotarget.26913","article-title":"Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma","volume":"10","author":"Apostolou","year":"2019","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/030089160609200506","article-title":"Selected hypoxic stop-flow perfusions: Indication and limits","volume":"92","author":"Guadagni","year":"2006","journal-title":"Tumori"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejso.2006.10.042","article-title":"Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: A phase II evaluation\/trial","volume":"33","author":"Guadagni","year":"2007","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Aigner, K.R., and Stephens, F.O. (2016). The role of hypoxia and hyperthermia in chemotherapy. Induction Chemotherapy. Systemic and Locoregional, Springer. [2nd ed.].","DOI":"10.1007\/978-3-319-28773-7"},{"key":"ref_55","first-page":"4811","article-title":"Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH","volume":"57","author":"Gabr","year":"1997","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response valuation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_57","first-page":"411","article-title":"Pilot studies","volume":"17","author":"Connelly","year":"2008","journal-title":"Medsurg. Nurs."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1900100","DOI":"10.1002\/adtp.201900100","article-title":"Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy","volume":"3","author":"Popova","year":"2020","journal-title":"Adv. Therap."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:42Z","timestamp":1760176122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":58,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21134813"],"URL":"https:\/\/doi.org\/10.3390\/ijms21134813","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}